IDEXX Laboratories, Inc.
IDXXIDEXX wins by embedding its machines, software, and lab services into veterinary clinics, turning everyday pet care into predictable, high-margin revenue.
Because once its systems are inside a clinic, they are hard to remove and quietly compound for years.
Business Model
Devices plus services
Sells diagnostic machines to vet clinics, then earns recurring revenue from test consumables and lab services.
Economic Engine
High cash generation
61.8% gross margins and 24.6% net margins convert almost every dollar of profit into cash.
Long-Term Lens
Ecosystem durability
The key question is whether clinics stay loyal to its integrated testing and software platform over decades.
BinaPrint Snapshot
Style
Build
Fitness
Mixed
Updated Mar 8, 2026
On this page
Company Story
How do IDEXX Laboratories, Inc.'s business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“IDEXX is a high-margin, recurring revenue engine tied to the humanization of pets, with durable economics if it can defend its clinic ecosystem.”
What does IDEXX Laboratories, Inc. actually do?
IDEXX makes diagnostic tests and equipment that veterinarians use to check the health of pets and livestock.
- Sells in-clinic machines that run blood, urine, and other diagnostic tests.
- Operates reference laboratories that handle more complex testing.
- Provides software that helps vet clinics manage records and workflows.
Why it matters
It sits at the center of pet healthcare decisions.
When a vet wants fast, reliable answers about a pet’s health, IDEXX is often the system doing the testing.
How does IDEXX Laboratories, Inc. make money?
IDEXX makes money by placing diagnostic machines in clinics and then selling the tests, supplies, and services those machines require.
- Recurring revenue from consumables used every time a test is run.
- Fees from laboratory testing services.
- Software subscriptions tied to clinic management systems.
Economic clue
24.5% free cash flow margin.
Nearly a quarter of revenue turns into free cash flow, showing strong pricing power and repeat usage.
Why do long-term investors keep IDEXX Laboratories, Inc. on the radar?
IDEXX is tied to the long-term trend of people spending more on their pets’ health.
- Revenue grew 7.6% per year on average over the past five years.
- Earnings per share grew 10.8% per year on average over five years, faster than revenue.
- Margins are expanding, with operating margin at 31.6%.
Investor takeaway
A compounding engine.
When revenue, margins, and share count all move in the right direction, long-term owners can see powerful compounding.
Based on company financial statements.
What Could Change The Story
- Proved it would move the profile toward Summit.
- Building would move the profile toward Flash.
Benchmark Comparison
How has IDEXX Laboratories, Inc. performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$1,218
+21.8% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| IDXX | +21.8% | $1,218 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame IDEXX Laboratories, Inc.
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to the long-term growth of pet healthcare spending.
- A high-margin business with recurring revenue.
- A company that reinvests and buys back shares instead of paying dividends.
Be Careful If You Expect
- A high dividend income stream, there is currently no dividend.
- Explosive hypergrowth, revenue has grown in the high single digits on average.
- Zero competitive pressure, large healthcare companies could target this niche.
What To Watch Over Time
- Sustained revenue growth around or above its 7.6% five-year average.
- Whether operating margin stays above 30% as it scales.
- Continued disciplined share buybacks without overpaying.
BinaPrint Position
Where does IDEXX Laboratories, Inc. sit on the BinaPrint map right now?
Test whether business quality and financial profile match the company's stated narrative.
Advanced BinaPrint details
Open the axes, investor fit, and risk framing behind this profile.
Key Metrics
Which metrics matter most for IDEXX Laboratories, Inc. right now?
Three durable business metrics that matter more than day-to-day price moves.
7.6% per year
10.8% per year
61.8% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 7.6% per year | Shows whether the business has been expanding fast enough to create more long-term value. |
| EPS Growth | 10.8% per year | Shows whether earnings per share are compounding for owners over time. |
| Margin Quality | 61.8% gross margin | Shows how much room the business has to fund growth, absorb shocks, and stay profitable. |
Based on company financial statements.
Fundamentals
What do IDEXX Laboratories, Inc.'s fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
39.1% ROIC
61.8% gross margin
24.5% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 39.1% ROIC | The business is currently showing excellent capital efficiency. |
| Profitability | 61.8% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 24.5% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold IDEXX Laboratories, Inc.?
IDEXX Laboratories, Inc. currently appears in these ETF and fund proxies.
QQQ
Invesco QQQ Trust, Series 1
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about IDEXX Laboratories, Inc.?
Company-specific questions readers often ask about IDEXX Laboratories, Inc..
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
IDEXX makes diagnostic machines, tests, and software that veterinarians use to diagnose and manage pet health.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
The humanization of pets continues, with owners willing to pay for advanced diagnostics, supporting steady demand growth for decades.
Once IDEXX equipment and software are embedded in a clinic, switching costs are high due to workflow disruption and staff retraining.
61.8% gross margins and 31.6% operating margins provide room to invest in research, sales, and software while still generating strong profits.
Consistent share buybacks, 1.2 billion dollars in the last 12 months, concentrate ownership and amplify long-term earnings per share growth.
Bear case
What can break
A large healthcare or diagnostics company could aggressively enter veterinary testing, compressing margins in what is ultimately a specialized but not impregnable niche.
If pet spending slows due to prolonged economic pressure, discretionary tests could be delayed, reducing consumables volume.
Technological disruption, such as cheaper or more automated testing platforms, could weaken IDEXX’s pricing power over time.
Veterinary clinic consolidation could increase buyer power, pushing down prices and narrowing margins.
Risk Radar
Key Risks
Where downside pressure can build.
Customer concentration in veterinary clinics, a slowdown in clinic activity could directly reduce consumables revenue that drives margins.
Margin compression risk, with operating margin at 31.6%, even a 5 percentage point decline would meaningfully reduce net profit.
Execution risk in software and innovation, failure to keep systems current could weaken switching costs.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $608.41
- Daily move
- -1.70%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.